[go: up one dir, main page]

PE20120424A1 - Compuestos de quinazolina sustituidos - Google Patents

Compuestos de quinazolina sustituidos

Info

Publication number
PE20120424A1
PE20120424A1 PE2011001296A PE2011001296A PE20120424A1 PE 20120424 A1 PE20120424 A1 PE 20120424A1 PE 2011001296 A PE2011001296 A PE 2011001296A PE 2011001296 A PE2011001296 A PE 2011001296A PE 20120424 A1 PE20120424 A1 PE 20120424A1
Authority
PE
Peru
Prior art keywords
substitute
diseases
heteroaryl
aryl
phenyl
Prior art date
Application number
PE2011001296A
Other languages
English (en)
Inventor
Caroline Leriche
David N Middlemiss
Eric Auclair
Roux Jacques Le
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41735344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120424(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of PE20120424A1 publication Critical patent/PE20120424A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE R1 Y R2 SON CADA UNO H, ALQUILO C1-C4, ARILO, HETEROARILO, -CN, -HALOGENO, ENTRE OTROS; R3 ES H, ALQUILO C1-C4, CICLOALQUILO, ARILO, HETEROARILO, -CN, -CF3, ENTRE OTROS; X ES DE PREFERENCIA UN ENLACE. SON COMPUESTOS PREFERIDOS: [6-(2,6-DIETIL-FENIL)-QUINAZOLIN-2-IL]-[4-(2-PIRROLIDIN-1-IL-ETOXI)-FENIL]-AMINA; 4-CLORO-3-[2-(3-HIDROXIMETIL-FENILAMINO)-8-METIL-QUINAZOLIN-6-IL]-FENOL; ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DE CINASA SELECTIVOS UTILES EN EL TRATAMIENTO DE QUE INCLUYE ENFERMEDADES CARDIOVASCULARES, DIABETES, ENFERMEDADES INFLAMATORIAS, CANCER Y OTRAS ENFERMEDADES COMO RINOPATIAS O DEGENERACION MACULAR, ENTRE OTRAS
PE2011001296A 2008-12-29 2009-12-18 Compuestos de quinazolina sustituidos PE20120424A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08360043 2008-12-29

Publications (1)

Publication Number Publication Date
PE20120424A1 true PE20120424A1 (es) 2012-05-04

Family

ID=41735344

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001296A PE20120424A1 (es) 2008-12-29 2009-12-18 Compuestos de quinazolina sustituidos

Country Status (23)

Country Link
US (1) US8389530B2 (es)
EP (1) EP2381943A1 (es)
JP (1) JP2012514020A (es)
KR (1) KR20110120878A (es)
CN (1) CN102333533A (es)
AU (1) AU2009334869A1 (es)
BR (1) BRPI0924067A2 (es)
CA (1) CA2748319A1 (es)
CO (1) CO6390105A2 (es)
CR (1) CR20110368A (es)
DO (1) DOP2011000209A (es)
EA (1) EA019110B1 (es)
EC (1) ECSP11011204A (es)
IL (1) IL213742A0 (es)
MA (1) MA32968B1 (es)
MX (1) MX2011007064A (es)
NI (1) NI201100134A (es)
NZ (1) NZ593949A (es)
PE (1) PE20120424A1 (es)
SG (1) SG172415A1 (es)
TN (1) TN2011000319A1 (es)
WO (1) WO2010076238A1 (es)
ZA (1) ZA201104777B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081960A1 (es) 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
ES2916220T3 (es) 2012-07-11 2022-06-29 Blueprint Medicines Corp Inhibidores del receptor de factor de crecimiento de fibroblasto
SMT202200292T1 (it) 2013-10-25 2022-09-14 Blueprint Medicines Corp Inibitori del recettore del fattore di crescita dei fibroblasti
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
KR101715448B1 (ko) * 2014-07-16 2017-03-20 주식회사 큐리언트 염증성 질환 치료용 화합물
MX2017008520A (es) 2014-12-24 2018-03-01 Gilead Sciences Inc Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
AU2015371257B2 (en) 2014-12-24 2018-09-06 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of HIV
CN112239459B (zh) * 2019-07-19 2021-11-26 中国科学院上海药物研究所 稠环嘧啶氨基化合物、其制备方法、药物组合物及应用
WO2021254464A1 (zh) * 2020-06-19 2021-12-23 南京红云生物科技有限公司 取代喹唑啉类化合物、其制备方法、药物组合及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2386955A1 (en) * 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
ATE433967T1 (de) 2003-01-17 2009-07-15 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
AU2004281154A1 (en) 2003-10-16 2005-04-28 Novartis Vaccines And Diagnostics, Inc. 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer
NZ551027A (en) 2004-04-08 2011-01-28 Targegen Inc Benzotriazine inhibitors of kinases
JP5275628B2 (ja) 2004-08-25 2013-08-28 ターゲジェン インコーポレーティッド 複素環式化合物および使用方法
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
AU2006227628A1 (en) 2005-03-16 2006-09-28 Targegen, Inc. Pyrimidine compounds and methods of use
WO2006118256A1 (ja) 2005-04-28 2006-11-09 Kyowa Hakko Kogyo Co., Ltd. 2-アミノキナゾリン誘導体
WO2006133411A1 (en) 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
EA200900819A1 (ru) * 2006-12-22 2010-02-26 Новартис Аг Хиназолины для ингибирования pdk1

Also Published As

Publication number Publication date
EA019110B1 (ru) 2014-01-30
AU2009334869A2 (en) 2011-09-29
WO2010076238A1 (en) 2010-07-08
NZ593949A (en) 2013-08-30
NI201100134A (es) 2012-03-06
CA2748319A1 (en) 2010-07-08
EP2381943A1 (en) 2011-11-02
EA201101012A1 (ru) 2012-01-30
ZA201104777B (en) 2012-03-28
CO6390105A2 (es) 2012-02-29
IL213742A0 (en) 2011-07-31
TN2011000319A1 (en) 2012-12-17
CN102333533A (zh) 2012-01-25
DOP2011000209A (es) 2011-09-30
ECSP11011204A (es) 2011-10-31
US20120004210A1 (en) 2012-01-05
SG172415A1 (en) 2011-07-28
JP2012514020A (ja) 2012-06-21
BRPI0924067A2 (pt) 2016-01-26
CR20110368A (es) 2011-12-02
MA32968B1 (fr) 2012-01-02
KR20110120878A (ko) 2011-11-04
AU2009334869A1 (en) 2011-07-14
US8389530B2 (en) 2013-03-05
MX2011007064A (es) 2012-01-20

Similar Documents

Publication Publication Date Title
PE20120424A1 (es) Compuestos de quinazolina sustituidos
BR112014005226A2 (pt) derivados de benzonitrila como inibidores de cinase
CO6612267A2 (es) Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
AR082799A1 (es) Derivados de quinolina y quinoxalina como inhibidores de quinasa
CR10233A (es) Piridin-4-ilmetilamidas
MX2014002836A (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
PE20160026A1 (es) Compuestos heterociclicos como agentes para control de plagas
CU24083B1 (es) Derivados de oxazina útiles como inhibidores de bace para el tratamiento de trastornos neurológicos
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
PE20141540A1 (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
CY1117197T1 (el) Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ
BR112013029640A2 (pt) derivados de piridina e pirazina
MX344669B (es) Agente antiplaquetas novedoso.
UY32606A (es) Sulfonamidas nematocidas
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20121180A1 (es) (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer
EA201201648A1 (ru) Стимуляторы sgc
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
PE20080059A1 (es) Quinazolinas para la inhibicion de pdk1
EA201170099A1 (ru) Замещенные пиримидин-4-оновые производные
PE20110419A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk

Legal Events

Date Code Title Description
FC Refusal